Back to Search
Start Over
Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis.
- Source :
- Acta Dermato-Venereologica; 2022, Vol. 102, p1-2, 2p
- Publication Year :
- 2022
-
Abstract
- The article presents a study which aims to evaluate 1- and 2-year drug survival (DS) of guselkumab, split for discontinuation due to ineffectiveness or side-effects. It mentions that the study elucidate predictors for a shorter guselkumab DS. It informs that guselkumab has been registered as the first interleukin-23 (IL-23) inhibitor for treatment of psoriasis.
- Subjects :
- PSORIASIS
PSORIATIC arthritis
TYPE 2 diabetes
Subjects
Details
- Language :
- English
- ISSN :
- 00015555
- Volume :
- 102
- Database :
- Complementary Index
- Journal :
- Acta Dermato-Venereologica
- Publication Type :
- Academic Journal
- Accession number :
- 161258884
- Full Text :
- https://doi.org/10.2340/actadv.v102.685